Dr Roy D Evans, MD | |
4297 Highway 42, Bassfield, MS 39421-4424 | |
(601) 943-5060 | |
(601) 943-5888 |
Full Name | Dr Roy D Evans |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 4297 Highway 42, Bassfield, Mississippi |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1952465619 | NPI | - | NPPES |
01456013 | Medicaid | MS | |
0111136 | Medicaid | MS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 13317 (Mississippi) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Roy D Evans, MD Po Box 68, Bassfield, MS 39421-0068 Ph: (601) 943-5060 | Dr Roy D Evans, MD 4297 Highway 42, Bassfield, MS 39421-4424 Ph: (601) 943-5060 |
News Archive
The presence of certain bacteria in the mouth may reveal increased risk for pancreatic cancer and enable earlier, more precise treatment. This is the main finding of a study led by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center to be presented April 19 in New Orleans at the annual meeting of the American Association for Cancer Research.
Obesity is now considered a global health epidemic, affecting millions of people worldwide. In morbidly obese patients, the extra weight has taken a toll on their overall health, including predisposing them to cardiovascular disease, type 2 diabetes, certain cancers, and respiratory issues. However, breathing issues in obese people may be reversed and relieved, thanks to weight loss surgery.
A growing number of women forgoing reconstruction after a mastectomy say they're satisfied with their choice, even as some did not feel supported by their physician, according to a study led by researchers at the UCLA Jonsson Comprehensive Cancer Center.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) approved EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the treatment of hypertension to lower blood pressure in adults.
As the world's largest professional society concerned with the causes and treatment of blood disorders, many of ASH's more than 16,000 members are on the front lines of dealing with the country's severe shortage of methotrexate, a drug critical in the treatment of children with acute lymphocytic leukemia.
› Verified 1 days ago